Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m |
|||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Acute lymphocytic leukemia]]=== | ===[[Acute lymphocytic leukemia]]=== | ||
| − | # Advani | + | # Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [http://www.ncbi.nlm.nih.gov/pubmed/24579885 PubMed] [http://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 03:10, 26 November 2014
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article